- Index hide
According to Statista, in 2019, about 24.3% of deaths in the United Arab Emirates were attributed to obesity.
According to Statista, in 2019, there were about 218 deaths per 100 thousand inhabitants in Egypt due to obesity.
In 2019, more than 30% of adults, both men and women, in the United States were reported to be obese.
Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation.
The small Phase I trial of the experimental drug found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133.
Amgen shares have gained about 5% since the company said on November 7 that 12 weeks of test treatment with the highest monthly dose of AMG133 resulted in an average weight loss of 14.5%.
At 150 days after the last dose, sustained weight loss was reduced to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of the World Congress on Insulin Resistance, Diabetes and Disease. Cardiovascular in Los Angeles.
Patients treated with AMG133 had side effects, including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.
The US Centers for Disease Control and Prevention estimates that more than 40% of the US population is obese, costing nearly $173 billion a year. It’s a leading cause of type 2 diabetes and has been linked to heart disease, certain cancers, and other health complications, including the more serious COVID-19.
Related notes: